Genzyme Corp. is inching closer to its goal of becoming a leader in multiple sclerosis treatment. The Cambridge, Mass.-based Sanofi subsidiary has won Canadian approval for its much-anticipated multiple sclerosis therapy, Lemtrada.
Genzyme Corp. is inching closer to its goal of becoming a leader in multiple sclerosis treatment. The Cambridge, Mass.-based Sanofi subsidiary has won Canadian approval for its much-anticipated multiple sclerosis therapy, Lemtrada.
